Adds details, share reaction, CEO comment JERUSALEM, May 10 (Reuters) - Israel-based Teva Pharmaceutical Industries TEVA.TA reported a drop in first-quarter profit that fell way short of estimates, saying it was hurt by rising costs due to inflationary and other macroeconomic pressures. Analysts had forecast Teva TEVA.N would earn 56 cents a share ex-items on revenue of $3.63 billion, according to I/B/E/S data from Refinitiv. For 2023, Teva maintained its forecast of adjusted EPS of $2.25-$2.55 and revenue of $14.8-$15.4 billion, compared with adjusted EPS of $2.52 and revenue of $14.9 billion in 2022.